Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENGRAF vs ELIDEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.
Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.
Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants,Treatment of active rheumatoid arthritis (FDA-approved for moderate to severe),Treatment of psoriasis (FDA-approved for severe, recalcitrant cases),Off-label: nephrotic syndrome, aplastic anemia, ulcerative colitis, atopic dermatitis
Atopic dermatitis unresponsive to or intolerant of other topical treatments,Off-label: psoriasis, vitiligo, rosacea, contact dermatitis, lichen sclerosus, cutaneous lupus erythematosus
5-15 mg/kg/day orally in divided doses every 12 hours.
Apply a thin layer of 1% cream to affected areas twice daily.
Terminal half-life is approximately 8.4 hours (range 5-18 hours) in adult volunteers; prolonged in hepatic impairment.
Terminal elimination half-life: 30–45 hours (mean 35 hours) following topical application; clinically, twice-daily dosing ensures therapeutic concentrations.
Hepatic metabolism primarily via CYP3A4 enzyme; also substrate for CYP3A5. Metabolized to multiple metabolites with variable activity, including AM1 (hydroxylated), AM9 (N-demethylated), and AM4N (cyclized). Undergoes extensive first-pass metabolism.
Metabolized primarily by CYP3A4; major metabolite O-demethylated pimecrolimus.
Primarily biliary/fecal (94%); renal excretion accounts for 6% (0.1% unchanged).
Renal (negligible, <1% unchanged) and biliary/fecal (approximately 97% as metabolites); less than 1% of the dose is excreted renally as unchanged drug.
90-98% bound to plasma proteins, primarily lipoproteins, albumin, and alpha-1-acid glycoprotein.
99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
3.5 L/kg (range 1.2-4.8 L/kg) in renal transplant recipients; distribution is extensive and variable.
Vd ~ 10 L/kg (extensive tissue distribution); suggests significant extravascular binding and penetration into tissues.
Oral bioavailability is 30% (range 10-60%), variable due to first-pass metabolism and food effects.
Topical: Systemic bioavailability is approximately 4% (range 1–7%) of applied dose; absorption increases with extent of skin lesion and thickness of application.
GFR <30 m L/min: reduce dose by 50%.
No dose adjustment required for any degree of renal impairment.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
No formal studies in hepatic impairment; use caution in severe impairment.
4-10 mg/kg/day orally in divided doses every 12 hours; adjusted to target trough levels.
Apply a thin layer of 1% cream twice daily for children aged 2 years and older; not indicated for children under 2 years.
Initiate at lower end of dosing range and titrate based on renal function and drug levels.
No specific dose adjustment recommended; apply a thin layer of 1% cream twice daily as for adults.
Increased susceptibility to infection and development of lymphoma and other malignancies, particularly of the skin. Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe cyclosporine.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; use should be limited to short-term and intermittent treatment.
Nephrotoxicity: Monitor renal function regularly; risk increased with high doses, other nephrotoxic drugs, or prolonged use.,Hepatotoxicity: Monitor liver function.,Hypertension: Common; require blood pressure control.,Neurotoxicity: Including tremor, convulsions, headache, and paresthesias.,Hyperkalemia: Monitor serum potassium, especially with potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Supplementation may be required.,Increased risk of infections and lymphoproliferative disorders.,Potential for anaphylactic reactions with IV formulation (due to Cremophor EL).,Carcinogenesis: Especially skin malignancies; minimize UV exposure.
Increased risk of infections (e.g., eczema herpeticum, varicella zoster); avoid use on malignant or premalignant skin conditions; lymphadenopathy; photosensitivity; not recommended in patients with Netherton syndrome; potential for systemic immunosuppression; monitor for local irritation.
Hypersensitivity to cyclosporine or any component of the formulation (including Cremophor EL for IV),Uncontrolled hypertension,Malignancy (except non-melanoma skin cancer) in patients with rheumatoid arthritis or psoriasis,Concomitant use with PUVA or UVB therapy, methotrexate, other immunosuppressive agents, or coal tar (for psoriasis patients),Abnormal renal function with uncontrolled hypertension (for psoriasis patients),Pregnancy (category C; additional risk of premature birth and low birth weight)
Hypersensitivity to pimecrolimus or any component of the formulation; history of malignancy; application to areas of active infection; Netherton syndrome; immunocompromised patients.
Grapefruit and grapefruit juice increase cyclosporine levels and must be avoided. High-potassium foods (e.g., bananas, oranges, potatoes) may increase hyperkalemia risk; monitor intake. Avoid St. John's wort as it reduces drug levels.
No known food interactions. Avoid grapefruit juice as it may increase drug levels (CYP3A4 inhibition).
First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction, prematurity, and low birth weight. Consider risk-benefit; avoid if possible, but may be used if essential.
FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be excluded. Avoid in pregnancy unless clearly needed.
Cyclosporine is excreted into breast milk. Milk-to-plasma ratio approximately 0.3-0.6. Potential for infant immunosuppression and growth inhibition. Weigh benefits against risks; monitor infant for adverse effects.
Not recommended. Pimecrolimus is excreted in milk in animal studies; unknown in humans. M/P ratio not available. Potential for serious adverse reactions in nursing infants.
Pregnancy reduces cyclosporine oral bioavailability and increases clearance; dose may need to be increased by 20-50% to maintain therapeutic trough levels. Frequent level monitoring recommended, especially in third trimester. Postpartum dose reduction likely needed.
No dose adjustment necessary; use minimal amount to control symptoms. Systemic absorption is negligible, so pharmacokinetic changes in pregnancy do not alter dosing.
Monitor trough levels (target 100-400 ng/m L) and renal function closely. Calcineurin inhibitors cause nephrotoxicity; dose reduction may be necessary. Avoid use with potassium-sparing diuretics or ACE inhibitors due to hyperkalemia risk. Grapefruit increases levels; avoid coadministration. Remember to adjust dose for hepatic impairment.
Topical calcineurin inhibitor for atopic dermatitis, reserved as second-line therapy for mild-to-moderate eczema due to boxed warning for rare malignancy risk. Apply thin layer only; avoid occlusive dressings. Do not use in immunocompromised patients. Intermittent use is recommended; continuous long-term use safety not established.
Take with or without food consistently at the same times each day.,Do not consume grapefruit or grapefruit juice while on this medication.,Report signs of infection, tremors, or changes in urine output immediately.,Avoid live vaccinations and limit sun exposure due to increased skin cancer risk.,Do not stop or change dose without consulting your doctor.
Apply only to affected skin areas; avoid eyes, mouth, and open wounds.,Use for short durations; do not use continuously for extended periods.,Avoid sun exposure and tanning beds; use sunscreen on treated areas.,Do not cover treated skin with bandages or wraps unless instructed.,Report any signs of infection, skin burning, or new skin growths to your doctor.,This drug is for external use only; wash hands after application unless treating hands.,Do not use if you have a weakened immune system or active skin infection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENGRAF vs ELIDEL, answered by our medical review team.
GENGRAF is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.. ELIDEL is a Topical Calcineurin Inhibitor that works by Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENGRAF and ELIDEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENGRAF is: 5-15 mg/kg/day orally in divided doses every 12 hours.. The standard adult dose of ELIDEL is: Apply a thin layer of 1% cream to affected areas twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENGRAF and ELIDEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENGRAF is classified as Category C. First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction,. ELIDEL is classified as Category C. FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be ex. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.